journal article·2026-02Open access

Multifunctional Nano Immunostimulant: Overcoming Immunosuppressive Microenvironment for Antitumor Immunotherapy

Guanhong Guo, Wenda Zhong, Huishuang Zhao, Yueying An, Xinyu Dong, Zhengbo Li, Shuangfeng Qin, Guangzhao Xu, Xiangguo Yue, Xudong Wang, Wen Sun, Zhe‐Sheng Chen, Weiguo Song, Liuya Wei, Fahui Li

Advanced Science· Volume 13· Issue 12

Abstract

Abstract Antitumor immunotherapy has become a pillar therapy by activating the immune system to recognize and attack tumor cells. Yet its efficacy is limited by the immunosuppressive tumor microenvironment (TME) and related mechanisms like hypoxia, high glutathione (GSH) expression, and immune evasion. Due to TME complexity and tumor heterogeneity, monotherapy struggles to modulate immunosuppressive factors for potent results. To solve this, this work develops a multifunctional immune stimulator (3IZH), which can simultaneously boost immunity, downregulate GSH, and alleviate hypoxia. In weakly acidic TME, it releases photosensitizer (3ICy5) and Fe ions. Fe ions consume GSH and relieve hypoxia via redox reactions and hydrogen peroxide decomposition. 3ICy5 accumulates in the endoplasmic reticulum (ER), produces ROS, induces severe ER stress and DAMPs release, triggering immunogenic cell death (ICD). Fe ions and ROS also reduce glutathione peroxidase 4 (GPX4), causing ferroptosis. ICD and ferroptosis activate T cell infiltration to restructure TME. Combined with HIF‐1α inhibitor digoxin, 3IZH further reduces HIF‐1α resistance, enhances immune cell infiltration, and shows satisfying efficacy in bilateral tumor‐bearing mice. The regulatory effect of the immune‐suppressive TME, the remarkable therapeutic effect, as well as the safety profile, together indicate the potential of the multifunctional immune stimulator design strategy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer, Hypoxia, and Metabolism · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmacy Shandong Second Medical University Weifang 261053 P. R. China

Weifang University of Science and Technology Weifang 262700 P. R. China

Harway Pharma (Weifang) Co., Ltd Weifang 262700 P. R. China

State Key Laboratory of Fine Chemicals Dalian University of Technology Dalian 116024 P. R. China

Department of Pharmaceutical Sciences College of Pharmacy and Health Sciences St. John's University New York NY 11439 USA

Funding

Natural Science Foundation of Shandong Province

References (38)

Show source-provided references
1. 10.1007/s12272‐021‐01355‐110.1007/s12272‐021‐01355‐1 ↗
2. 10.1016/j.ultsonch.2025.10740210.1016/j.ultsonch.2025.107402 ↗
3. 10.1002/advs.20250154210.1002/advs.202501542 ↗
4. 10.1073/pnas.202386811810.1073/pnas.2023868118 ↗
5. 10.1038/s41467‐022‐31764‐910.1038/s41467‐022‐31764‐9 ↗
6. 10.1038/s41388‐021‐01846‐x10.1038/s41388‐021‐01846‐x ↗
7. 10.1126/sciadv.ade511110.1126/sciadv.ade5111 ↗
8. 10.1016/j.immuni.2025.07.00810.1016/j.immuni.2025.07.008 ↗
9. 10.1016/j.celrep.2023.11294510.1016/j.celrep.2023.112945 ↗
10. 10.1016/j.canlet.2022.01.02710.1016/j.canlet.2022.01.027 ↗
11. 10.1155/2021/306037510.1155/2021/3060375 ↗
12. 10.1136/jitc‐2024‐01061210.1136/jitc‐2024‐010612 ↗
13. 10.1038/s41467‐017‐02696‐610.1038/s41467‐017‐02696‐6 ↗
14. 10.1093/neuonc/noad179.106110.1093/neuonc/noad179.1061 ↗
15. 10.1038/s42004‐022‐00661‐z10.1038/s42004‐022‐00661‐z ↗
16. 10.1158/0008‐5472.Can‐20‐167410.1158/0008‐5472.Can‐20‐1674 ↗
17. 10.1136/jitc‐2021‐00373110.1136/jitc‐2021‐003731 ↗
18. 10.1016/j.jcis.2025.13798010.1016/j.jcis.2025.137980 ↗
19. 10.1038/s41419‐024‐07327‐910.1038/s41419‐024‐07327‐9 ↗
20. 10.1186/s12951‐022‐01699‐w10.1186/s12951‐022‐01699‐w ↗
21. 10.1021/acs.inorgchem.2c0280610.1021/acs.inorgchem.2c02806 ↗
22. 10.1021/jacs.1c1188610.1021/jacs.1c11886 ↗
23. 10.1016/j.jconrel.2023.09.02410.1016/j.jconrel.2023.09.024 ↗
24. 10.1038/s41419‐022‐05112‐010.1038/s41419‐022‐05112‐0 ↗
25. 10.1073/pnas.241224612210.1073/pnas.2412246122 ↗
26. 10.3748/wjg.v29.i16.243310.3748/wjg.v29.i16.2433 ↗
27. 10.1016/j.critrevonc.2023.10424910.1016/j.critrevonc.2023.104249 ↗
28. 10.1002/adma.20230593210.1002/adma.202305932 ↗
29. 10.1016/j.bioactmat.2024.10.02410.1016/j.bioactmat.2024.10.024 ↗
30. 10.1155/2022/786243010.1155/2022/7862430 ↗
31. 10.1002/adhm.20230050310.1002/adhm.202300503 ↗
32. 10.18632/oncotarget.2875010.18632/oncotarget.28750 ↗
33. 10.1186/s40164‐023‐00419‐w10.1186/s40164‐023‐00419‐w ↗
34. 10.1038/s41419‐022‐05397‐110.1038/s41419‐022‐05397‐1 ↗
35. 10.2174/156652401866618092616321810.2174/1566524018666180926163218 ↗
36. 10.1158/1535‐7163.Mct‐19‐077610.1158/1535‐7163.Mct‐19‐0776 ↗
37. 10.1016/j.ctrv.2020.10201510.1016/j.ctrv.2020.102015 ↗
38. 10.1038/s41467‐021‐27801‐810.1038/s41467‐021‐27801‐8 ↗